Screener
ADMA Biologics ADMA Issuance of warrants
Issuance of warrants at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued.
The source filing: ADMA Biologics’s 10-K, filed February 25, 2026.
- Filed
- Feb 25, 2026, 5:16 PM EST
- Fiscal year
- FY2025
- Accession
- 0001140361-26-006815
| Line item | Common Stock / Shares | Common Stock / Amount | Additional / Paid-in / Capital | Accumulated / Deficit | Treasury Stock / Shares | Treasury Stock / Amount | Total / Stockholders' / Equity |
|---|---|---|---|---|---|---|---|
| Balance at December 31, 2022 | $221,816,930 | $22 | $629,969 | (478,017) | - | - | 151,974 |
| Stock-based compensation | - | - | 6,187 | - | - | - | 6,187 |
| Vesting of Restricted Stock Units, net of shares withheld for taxes | 833,722 | - | (1,415) | - | - | - | (1,415) |
| Warrants issued in connection with notes payable | - | - | 5,595 | - | - | - | 5,595 |
| Exercise of stock options | 1,444,533 | 1 | 1,103 | - | - | - | 1,104 |
| Cashless exercise of warrants | 1,967,847 | - | - | - | - | - | - |
| Net loss | - | - | - | (28,239) | - | - | (28,239) |
| Balance at December 31, 2023 | 226,063,032 | 23 | 641,439 | (506,256) | - | - | 135,206 |
Item 16.
FAQ
- What is ADMA Biologics's issuance of warrants?
- ADMA Biologics (ADMA) reported issuance of warrants of $1.4M in Q4 2023.
- What does issuance of warrants mean?
- This represents changes to additional paid-in capital resulting from the issuance of warrants. It reflects the equity impact of granting rights to purchase shares at a future date, often used as part of financing or incentive arrangements.
Ask your AI about ADMA Biologics's issuance of warrants.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude